Company Overview - American Shared Hospital Services (ASHS) is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services [3] - The company collaborates with major global Original Equipment Manufacturers (OEMs) to provide cutting-edge clinical treatment systems and software for cancer treatment [3] - ASHS offers a range of products including MR Guided Radiation Therapy Linacs, Advanced Digital Linear Accelerators, Proton Beam Therapy Systems, and Brachytherapy systems [3] Financial Results Announcement - The company will hold a conference call to discuss its second quarter 2024 financial results on August 14, 2024, at 6:30 PM ET [1] - A press release detailing the financial results will be issued after the market closes on the same day [1] Participation Information - Domestic callers can join the call by dialing 844.413.3972, while international callers can dial 412.317.5776 [2] - A simultaneous webcast will be available on the company's website and for institutional investors [2] - A replay of the call will be accessible until August 21, 2024, through specified phone numbers and the company's website [2]

Core Viewpoint - SKYX Technologies is set to host a Corporate Update call on August 12, 2024, to present its second quarter 2024 financial results, highlighting its mission to make homes and buildings smart, safe, and advanced as the new standard [1][2]. Group 1: Corporate Update Call Details - The Corporate Update call will take place on August 12, 2024, at 4:30 PM Eastern Time [1]. - Key participants in the call include Rani Kohen (Founder and Executive Chairman), Steve Schmidt (President), Lenny Sokolow (Co-CEO), and Marc Boisseau (CFO) [1]. - Dial-in information for the call includes a U.S./Canada number (1-877-269-7751) and an international number (1-201-389-0908) [1]. Group 2: Company Overview - SKYX holds over 97 issued and pending patents in the U.S. and globally, focusing on advanced-safe-smart platform technologies [2]. - The company owns more than 60 lighting and home décor websites, targeting both retail and commercial segments [2]. - SKYX emphasizes high quality and ease of use in its products, aiming to enhance safety and lifestyle in homes and buildings [2].

Core Points - American Shared Hospital Services (AMS) has commenced patient treatments at its new Radiation Therapy Facility, A.B. Radiocirugía y Radioterapia de Puebla, in Puebla, Mexico, which is located 80 miles from Mexico City [1] - AMS has established a Joint Venture (JV) with Guadalupe Amor Y Bien, holding 85% and 15% ownership interests respectively, to provide cancer treatment services at the facility [2] - The facility is equipped with an Elekta Versa HD linear accelerator, which is an upgrade from the previous equipment, and aims to serve a population of over six million people in the region [2] - The introduction of advanced treatment modalities, including IMRT, VMAT, SBRT, and Radiosurgery, is expected to significantly enhance patient outcomes and drive demand for services [3] - The JV aims to reduce patient travel for advanced care, as previously patients had to travel to Mexico City for treatment [3][2] Company Strategy - The expansion into Mexico is part of AMS's international strategy, which also includes existing Gamma Knife centers in Peru and Ecuador [3] - The company has announced a joint venture with Hospital San Javier to treat patients with advanced Leksell Gamma Knife technology in Guadalajara, Mexico [3] - AMS's VP of Sales and Business Development-International emphasized that the ability to offer additional treatment modalities will provide a competitive advantage in the region [3] Market Context - The facility had not operated since 2020, and the reintroduction of services is seen as a critical need for the local population [2] - The upgrade to the Versa linear accelerator is expected to generate significant demand due to its advanced capabilities, allowing for single-session treatments compared to multiple sessions required by other options [3]

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggrega ...

Core Viewpoint - Oncocyte Corp. will announce its second quarter 2024 financial results on August 8, 2024, followed by a conference call and webcast to discuss the results and highlights [1]. Company Overview - Oncocyte is a diagnostics technology company focused on providing clarity and confidence to physicians and patients through its tests [1]. - The company's key products include: - VitaGraft™, a clinical blood-based solid organ transplantation monitoring test - GraftAssure™, a research use only (RUO) blood-based solid organ transplantation monitoring test - DetermaIO™, a gene expression test assessing the tumor microenvironment to predict response to immunotherapies - DetermaCNI™, a blood-based monitoring tool for therapeutic efficacy in cancer patients [1]. Conference Call Details - The conference call will take place on August 8, 2024, at 5:00 p.m. Eastern Time, with a toll-free dial-in number for participants [1]. - A live webcast will be available on the company's website, and a replay will be accessible shortly after the call concludes [1].

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu the ...

Company Overview - Phytanix Bio is a preclinical stage pharmaceutical company focused on developing therapeutics based on cannabinoid and cannabinoid-like molecules [1][15] - The company was founded by former members of GW Pharmaceuticals, leveraging their extensive experience and intellectual property to create innovative therapies for serious unmet medical needs [15] Strategic Vision and Growth Potential - The newly released investor deck outlines Phytanix Bio's strategic vision, scientific advancements, and growth potential as it progresses towards next-generation cannabinoid medicines [1][10] - The global cannabis pharmaceuticals market was estimated at USD 3.4 billion in 2023 and is projected to grow at a CAGR of 53.3% from 2024 to 2030, indicating significant market opportunities for Phytanix Bio [13] Scientific and Clinical Progress - The investor deck provides detailed updates on the company's preclinical studies, research collaborations, and upcoming clinical milestones [14] - Phytanix Bio is developing lead product candidates aimed at treating treatment-resistant facial seizures and Painful Bladder Syndrome (PBS) [14] Intellectual Property Portfolio - The company holds exclusive intellectual property related to cannabinoid and cannabinoid-like medicines, including patents and proprietary technologies [14] Management Team - The leadership team includes experienced professionals such as CEO Barrett Evans, COO Colin Stott, and Chief Legal Officer Dominic Schiller, all of whom are former key members of GW Pharmaceuticals [14] Business Combination Agreement - Phytanix Bio has entered into a Business Combination Agreement with Chain Bridge I (Nasdaq: CBRG), a blank-check company, to facilitate a merger or similar business combination [3][10]

Core Insights - BLAQclouds, Inc. has engaged ZEUS Blockchain Partners to develop and manage the "BLAQ" token, which will operate on both Ethereum and ZEUS blockchains [1][4] - The BLAQ token will have a total supply of 500 million tokens, with a planned price of $0.01 per token and a pre-launch price of $0.005 [1][5] - The BLAQ token will integrate with the DiVinciPay merchant platform, allowing holders to use BLAQ tokens as currency at participating merchants [1] Token Details - The BLAQ token will utilize layered smart contracts for funding liquidity pools on the ZEUS Chain, automating funding and managing distributions via time-locked contracts [5] - The token will operate under the ERC20 and ZRC20 standards, with a contract address of 0x81324d217089CEe039e3b660d9265FfeBBF534cD [1] - There will be no reflections or taxes associated with the BLAQ token, and the Uniswap pool fee is set at 0.03% [1] Company Overview - BLAQclouds, Inc. is a publicly traded company based in Nevada, specializing in artificial intelligence and innovative blockchain technology solutions [6] - The company aims to deliver high-performance, secure, and scalable AI-powered blockchain solutions, focusing on future growth and value addition for shareholders [6] - The company has updated its communication strategy, urging shareholders to disregard past social media posts and to rely on verified channels for information [2]

Core Insights - AmpliTech Group, Inc. has launched new Cryogenic Power Supplies designed for the quantum computing industry, available in two models with adjustable low-voltage outputs [1][2] - The new products complement the existing line of cryogenic low noise amplifiers, showcasing the company's commitment to innovation in critical industries [2] - AmpliTech Group operates multiple divisions and serves various global markets, including telecommunications, satellite communications, and quantum computing [3] Product Details - The Cryogenic Power Supplies are ergonomic bench-top models ideal for reliability testing, laboratory instrument testing, and cryogenic amplifier testing [1] - The products are available for individual purchase or as a set with AmpliTech's cryogenic amplifiers [1] Company Overview - AmpliTech Group, Inc. consists of five divisions and is a leading designer, developer, manufacturer, and distributor of RF microwave components and 5G network solutions [3] - The company is focused on advancing technology and innovation across various sectors, including space exploration and defense [3]

Core Viewpoint - AmpliTech Group is committed to executing its business plan and delivering innovative products in the communications sector, particularly in 5G and quantum computing, while addressing recent challenges and maintaining strong financial discipline [2][3][4][6]. Company Developments - The company has not engaged in digital currency investments, and any past incidents related to fraudulent activity have been reported to authorities [3]. - AmpliTech has a history of no debt and avoidance of dilutive financing, reflecting its commitment to shareholder equity [3]. Product Innovations - AmpliTech has developed several new products for Public and Private 5G, LEO Satellite constellations, and quantum computing, positioning itself in rapidly growing industrial sectors with total addressable markets exceeding trillions of dollars [4]. - The company is the only US-based manufacturer of a full suite of private and commercial 5G radios, providing data speeds over 1 Gbps, which are essential for modern applications like the Metaverse and automated vehicles [4]. - AmpliTech also produces cryogenic Low Noise Amplifiers (LNAs) for quantum computers and LNBs with the lowest noise figures in the industry, crucial for satellite communications [4]. Strategic Vision - The company has evolved from a single product focus to a comprehensive communications systems provider, demonstrating dedication and progress since its uplisting to Nasdaq [5]. - AmpliTech maintains a robust pipeline of leads and continues to sell new products through its online store, generating daily revenue [6]. - The management team is focused on advancing technology development and maintaining a leadership position in key markets, including 5G and quantum computing [6].